Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Forte Biosciences, Inc.NASDAQ: FBRX
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 41.6% from a year ago
Total assets stood at $67.22M at the end of Q1 FY2026, up 41.6% from a year earlier and down 18.8% from the prior quarter. Over 3 fiscal years it compounded at +25.4% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +41.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 82.78M USD
- Year-over-year change
- +34.5%
- 4-year CAGR
- +17.6%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 82.78M | +34.5% |
| FY2024 | 2024-12-31 | 61.56M | +57.9% |
| FY2023 | 2023-12-31 | 38.98M | -7.2% |
| FY2022 | 2022-12-31 | 42M | -3.0% |
| FY2021 | 2021-12-31 | 43.31M | — |
Total Assets vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +41.6% is the 2nd highest of 10, against a peer median of -20.9%.
- Over three fiscal years its annual growth of +25.4% compares with a peer median of -11.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $372.07M USD | -20.9% | -5.1% | |
| Mar 2026 | $284.92M USD | -28.5% | -23.3% | |
| Mar 2026 | $239.92M USD | -41.2% | -28.1% | |
| Mar 2026 | $156.3M USD | +22.7% | -7.2% | |
| Mar 2026 | $144.48M USD | +3.3% | +36.4% | |
| Mar 2026 | CHF 87.4M CHF | -38.1% | -27.0% | |
| Mar 2026 | $67.22M USD | +41.6% | +25.4% | |
| Mar 2026 | $49.17M USD | -42.0% | -18.9% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $22.69M USD | -19.4% | +4.5% |
ACTUActuate Therapeutics Inc | Mar 2026 | $8.91M USD | +98.8% | -11.8% |
| Peer median (excluding FBRX) | — | -20.9% | -11.8% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.